American Heart Journal Plus · Oct 28, 2026
SGLT2 inhibitors for peripartum cardiomyopathy: A call for a dedicated trial
By Acharya B
Peripartum cardiomyopathy (PPCM) accounts for more than 60% of pregnancy-related cardiogenic shock in the United States, yet specific evidence-based therapies remain limited. Despite guideline-directed medical therapy for heart failure with reduced ejection fraction, left ventricular ejection fraction recovery is incomplete in up to 50% of patients, and mortality reaches 20% in high-risk populations. A recent propensity-matched cohort of 10,907 PPCM patients found that sodium-glucose co-transporter 2 inhibitor (SGLT2i) use was associated with reduced all-cause mortality (HR 0.48, 95% CI 0.25-0.92), heart failure exacerbation (HR 0.83, 95% CI 0.76-0.90), and all-cause re-hospitalization (HR 0.81, 95% CI 0.70-0.93), corroborated by two independent case reports showing rapid left ventricular ejection fraction recovery on empagliflozin-containing regimens. However, residual confounding, notably a significant baseline left ventricular ejection fraction imbalance despite matching (35.0% vs. 45.0%; P < 0.01) and unreported bromocriptine use, limits causal inference. The convergence of real-world evidence, case reports, and mechanistic plausibility supports early SGLT2i consideration in appropriately selected PPCM patients. A dedicated randomized controlled trial, stratified by disease severity, lactation status, and race, and designed with careful ethical consideration, is now scientifically justified and ethically imperative.
doi.org/10.1016/j.ahjo.2026.101000Open accessPubMed 43022501Interventions